SEARCH

SEARCH BY CITATION

References

  • 1
    Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type-distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Intl J Cancer 2007; 121: 62132.
  • 2
    Muñoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijder PJF. Meijer CJLM. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 51827.
  • 3
    Garland SM, Steven M, Sings HL, James M, Lu S, Railkar R, Barr E, Haupt RM, Joura EA. Natural History of Genital Warts: analysis of the Placebo Arm of 2 Randomized Phase III Trials of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine. J Infect Dis 2009; 199: 80514.
  • 4
    Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler Cm, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 216170.
  • 5
    Muñoz N, Manalastas R, Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Meyers E, Hood S, Bautista O, Bryan J, et al. Safety, immunogenicity and efficacy of quadrivalent human papillomavirus (types 6,11,16,18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet 2009; 373: 194957.
  • 6
    Shefer A, Markowitz L, Deeks S, Tam T, Irwin K, Garland SM, Schuchat A. Early Experience with Human Papillomavirus Vaccine Introduction in the United States, Canada, and Australia. Vaccine 2008; 26, S10: K68K75.
  • 7
    Garland SM, Cuzick J, Domingo EJ, Goldie SJ, Kim YT, Konno R, Parkin DM, Qiao YL, Sankaranarayanan R, Stern PL, Tay SK, Bosch FX. Recommendations for Cervical Cancer Prevention in Asia Pacific. ICO Monograph Series on HPV and Cervical Cancer: Asia Pacific Regional Report. Vaccine 2008; 26s: M89M98.
  • 8
    Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skieldestad FE, Olsson SE. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 2718.
  • 9
    Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 192843.
  • 10
    The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 191527.
  • 11
    Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial [see comment]. Lancet 2004; 364: 175765.
  • 12
    Harper D, Gall S, Naud P, Quint W, Dubin G, Jenkins D, Schuind A. Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: long-term follow up through 6.4 years in women vaccinated with Cervarix™ (GSK's HPV 16/18 AS04 candidate vaccine). Gynecol Oncol 2008; 109: 158.43.
  • 13
    Lehtinen M, Idanpaan-Heikkila I, Lunnas T, Palmroth J, Barr E, Cacciatore R, Isaksson R, Kekki M, Koskela P, Kosunen E, Kuortti M, Lahti L, et al. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy. Int J STD AIDS 2006; 17: 23746.
  • 14
    Block SL, Nolan T, Sattler C, Barr E, Giacolette KE, Marchant CD, Castellsagué X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF, Jr, Reisinger KS, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118: 213545.
  • 15
    Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE, Lowy D, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007; 298: 74353.
  • 16
    Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DDR, Koutsky LA, Tay EH, García P, Ault KA, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and external anogenital disease in subjects with prior vaccine HPV type infection. Hum Vaccin 2009; 5: 696704.
  • 17
    Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA. Comparison of human papillomavirus types 16, 18 and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181: 191119.
  • 18
    Smith JS, Melendy A, Rana RK, Pimenta JM. Age-specific Prevalence of Infection with Human Papillomavirus: a global review. J Adolesc Health 2008; 43: S525, S25.e1–41.
  • 19
    Keita N, Clifford GM, Koulibaly M, Douno K, Kabba I, Haba M, Sylla BS, van Kemenade FJ, Snijders PJF, Meijer CJLM, Franceschi S. HPV infection in women with and without cervical cancer in Conakry, Guinea. Br J Cancer 2009; 101: 2028.
  • 20
    Thomas JO, Herrero R, Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A, Oladepo O, Smith JS, Arslan A, N Muñoz, Snijders PJF, Meijer CJLM, et al. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. Br J Cancer 2004; 90: 63845.
  • 21
    Belinson JL, Hu S, Niyazi M, Pretorius RG, Wang H, Wen C, Smith JS, Li J, Taddeo FJ, Burchette RJ, Qiao YL. Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perineal, and vaginal self-collected specimens; implications for vaginal self-collected specimens. Int J Cancer 2010; 127: 11517.
  • 22
    Belinson JL, Qiao YL, Pretorius R, Zhang WH, Elson P, Li L, Pan QJ, Fischer C, Lorincz A, Zahniser D. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparitive trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol. 2001; 83: 43944.
  • 23
    Sandri MT, Lentati P, Benini E, Dell'Orto P, Zorzino L, Carozzi FM, Maisonneuve P, Passerini R, Salvatici M, Casadio C, Boveri S, Sideri M. Comparison of the Digene HC2 Assay and the Roche AMPLICOR Human Papillomavirus (HPV) Test for Detection of High-Risk HPV Genotypes in Cervical Samples. J Clin Microbiol 2006; 44: 21416.
  • 24
    Mosonego J, Bohbot JM, Pollini G, Krawec C, Vincent C, Merignargues I, Haroun F, Sednaoui P, Monfort L, Dachez R, Syrgänan K. Performance of the Roche AMPLICOR® Human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear. Gynecol Oncol 2005; 99: 1608.
  • 25
    Smith JF, Kowalski R, Esser MT, Brown MJ, Bryan JT. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil®: a vaccine for human papillomavirus types 16, 18, 6, and 11. Hum Vaccin 2008; 4: 13442.
  • 26
    Dias D, Van Dorem J, Schlottman S, Kelly S, Puchalski D, Ruiz W, Boerckel P, Kessler J, Antonello JM, Green T, Brown M, Smith J, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16,and 18. Clin Diagn Lab Immunol 2005; 12: 95969.
  • 27
    Shin HR, Lee DH, Herrero R, Smith JS, Vaccarella S, Hong SH, Jung KY, Kim HH, Park UD, Cha HS, Park S, Touzé A, et al. Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer 2003; 103: 41321.
  • 28
    Dondog B, Clifford GM, Vaccarella S, Waterboer T, Unurgargal D, Avirmed D, Enkhtuya S, Kommoss F, Wentzensen N, Snijders PH, Meijer CJ, Franceschi S, et al. Human Papillomavirus Infection in Ulaanbaatar, Mongolia: a population-based study. Cancer Epidemiol Biomarkers Prev 2008; 17: 17318.
  • 29
    Paavonen J. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials. Curr Med Res Opin 2008; 24: 162334.
  • 30
    Vaccarella S, Franceschi S, Clifford GM, Touzé A, Hsu CC, de Sanjosé S, Anh PTH, Hieu NT, Matos E, Shin HR, Sukvirach S, Thomas JO, et al. Seroprevalence of antibodies against human papillomavirus (HPV) types 16 and 18 in four continents: the International Agency for Research on Cancer HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev 2010; 19: 237988.
  • 31
    Franceschi S, Smith JS, van den Brule A, Herrero R, Arslan A, Thomas JO, Matos E, Anh PTH, Hieu NT, Qiao Y-L, Sukvirach S, Shin HR, et al. Cervical infection with chlamydia trachomatis and gonorrhoea in women from ten areas in four continents. Sex Transm Dis 2007; 34: 5639.
  • 32
    Chen CJ, Viscidi RP, Chuang CH, Huang YC, Chiu CH, Lin TY. Seroprevalence of human papillomavirus types 16 and 18 in the general population in Taiwan: implication for optimal age of human papillomavirus vaccination. J Clin Virol 2007; 38: 12630.
  • 33
    Stone KM, Karem KL, Sternberg MR, McQuillan GM, Poon AD, Unger ER, Reeves WC. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 2002; 186: 1396402.
  • 34
    Sukvirach S, Smith JS, Tunsakul S, Muñoz N, Kesararat V, Opasatian O, Chichareon S, Kaenploy V, Ashley R, Meijer CJ, Snijders PJ, Coursaget P, et al. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis 2003; 187: 124656.
  • 35
    Wang SS, Schiffman M, Shields TS, Herrero R, Hildesheim A, Bratti MC, Sherman ME, Rodriguez AZ, Castle PE, Morales J, Alfaro M, Wright T, et al. Seroprevalence of human papillomavirus-16, −18, −31, and −45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer 2003; 89: 124854.
  • 36
    Burchell AN, Winer RL, de Sanjose S, Franco EL. Chapter 6: epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006; 24S3: S3/52S3/61.
  • 37
    Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: national health and nutrition examination survey 2003–2004. J Infect Dis 2009; 200: 105967.
  • 38
    Wu X, Zhang C, Feng S, Liu C, Li Y, Yang Y, Gao J, Li H, Meng S, Li L, Zhang Y, Hu X, et al. Detection of HPV types and neutralizing antibodies in Gansu province, China. J Med Virol 2009; 81: 693702.
  • 39
    Naucler P, Chen HC, Persson K, You SL, Hsieh CY, Sun CA, Dillner J, Chen CJ. Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: nested case-control study. J Gen Virol 2007; 88: 81422.
  • 40
    Matsumoto K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T. Antibodies to human papillomavirus 16, 18, 58, and 6b major capsid proteins among Japanese females. Jpn J Cancer Res 1997; 88: 36975.
  • 41
    Wang H, Qiao YL. Human papillomavirus type-distribution in condylomata acuminata of Mainland China: a meta-analysis. Int J STD AIDS 2008; 19: 6804.
  • 42
    Carter JJ, Koutsky LA, Wipf GC, Christensen ND, Lee SK, Kuypers J, Kiviat N, Galloway DA. The natural history of Human Papillomavirus Type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996; 174: 92736.
  • 43
    Malik ZA, Hailpern SM, Burk RD. Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV. Viral Immunol 2009; 22: 4459.
  • 44
    Skjeldestad FE, Mehta V, Sings HL, Ovreness T, Turpin J, Su L, Boerckel P, Roberts C, Bryan J, Jansen KU, Esser MT, Liaw KL. Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics. Acta Obstet Gynecol Scand 2008; 87: 818.
  • 45
    Marais DJ, Constant D, Allan B, Carrara H, Hoffman M, Shapiro S, Morroni C, Williamson AL. Cervical human papillomavirus (HPV) infection and HPV type 16 antibodies in South African women. J Clin Microbiol 2008; 46: 7329.